StockDrifts LogoStockDrifts

Genewon Life Science 011000

Company
진원생명과학Genewon Life Science
Insiders
2
Buys
0
Total Value
₩257M ($178K)
Avg Return
+22.84%
Last Filing
2026-06-29

Genewon Life Science (011000) has 0 disclosed insider purchases and 4 disclosed disposals on record, filed by 2 distinct insiders. Together those filings cover ₩257M ($178K) in reported transaction value. The earliest filing StockDrifts holds for Genewon Life Science is dated 2024-03-29; the most recent is 2026-06-29. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is +22.84%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-06-29SELL자본감소
정봉기
Bonggi Jeong
Outside Director-4.1K---
2026-03-27SELLMarket Sell
박희곤
Park Hee-gon
Managing Director-33.8K₩971+0.0%₩33M ($23K)
2026-03-25SELLMarket Sell
박희곤
Park Hee-gon
Managing Director-30.8K₩1,004+3.3%₩31M ($21K)
2025-08-12BUY신규선임
정봉기
Bonggi Jeong
Outside Director5.1K₩2,285-44.5%₩12M ($8K)
2025-05-15SELLMarket Sell
최성호
Seongho Choi
thanks-21.7K₩2,325+45.5%₩51M ($35K)
2025-04-28SELLMarket Sell
최성호
Seongho Choi
thanks-64.7K₩2,205+42.5%₩143M ($99K)
2025-03-26BUY신규선임
JOELNEAL MASLOW
group leader20.8K₩2,070-38.8%₩43M ($30K)
2025-01-14SELL시간외매매
박영근
Younggeun Park
CEO-700.0K₩2,450+48.3%₩1.7B ($1.2M)
2024-03-29BUY제3자배정유상증자
채재경
Chae Jae-kyung
moving60.0K₩2,535-50.0%₩152M ($106K)
2024-03-29BUY제3자배정유상증자
박영근
Younggeun Park
CEO1.3M₩2,535-50.0%₩3.3B ($2.3M)
2024-03-29BUY제3자배정유상증자
최성호
Seongho Choi
thanks21.7K₩2,535-50.0%₩55M ($38K)
2024-03-29BUY제3자배정유상증자
조병문
Jo Byeong-moon
Managing Director130.4K₩2,535-50.0%₩331M ($230K)

Frequently asked questions

Who has been buying Genewon Life Science stock?
2 distinct insiders have filed 0 disclosed insider purchases in Genewon Life Science (011000), most recently on 2026-06-29. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Genewon Life Science have?
Genewon Life Science has 0 buy-side and 4 sell-side disclosures on record, covering ₩257M ($178K) in total reported value, spanning 2024-03-29 to 2026-06-29.
Where does StockDrifts get Genewon Life Science insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Genewon Life Science. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.